

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re PATENT APPLICATION of

ZEICHER

Appln. No. 08/807,500

Filed: February 27, 1997

Title: NUCLEOTIDE SEQUENCE FOR TREATING
CANCER AND INFECTION



Group Art Unit: 1635

Examiner: McGarry, G.

11/B
D.G.
4/7/99
(NE)

* * * * *

April 2, 1999

AMENDMENT UNDER 37 C.F.R. § 1.116

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

Responsive to the Official Action mailed March 9, 1999 in the above-identified application, kindly consider and enter the following amendments and remarks.

IN THE CLAIMS:

Kindly cancel claims 2-3, 9, 11, 13-15, and 17-21 without prejudice or disclaimer.

Kindly amend the claims as follows.

1. (Twice Amended) A nucleotide sequence comprising the nucleotide

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT
APPLICATION


Inventor(s): ZEICHER

Appl. No.: 08

807,500

Series Code ↑

Serial No. ↑



Group Art Unit

1635

Examiner:

G. McGarry

Atty. Dkt. PMS

236007

PZCOM01/US

M#

Client Ref

Filed: February 27, 1997

Title: NUCLEOTIDE SEQUENCE FOR TREATING CANCER

Our Deposit Account No. 03-3975)

(Our Order No.

70401

236007

C#

M#

Asst. Commissioner of Patents
Washington, D.C. 20231

Date:

April 2, 1999

RECEIVED

Sir:

APR 06 1999

REPLY/AMENDMENT/LETTER

MAIL ROOM
SERVICE CENTER

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. "Small Entity" statement(s) filed		Claims remaining after amendment		Highest number previously paid for		Present Extra		Large/Small Entity		Additional Fee		Fee Code	
<input checked="" type="checkbox"/> previously <input type="checkbox"/> herewith (No.)													
2. Total Effective Claims		16		**minus 27		0		x \$18/\$9 =		+ 0		103/203	
3. Independent Claims		2		***minus 3		0		x \$78/\$39 =		+ 0		102/202	
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)		add						+ \$260/\$130 =		+ 0		104/204	
5. Original due Date: June 9, 1999		<input type="checkbox"/> NONE											
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo)		\$110/\$55 =								115/215	
		(2 mos)		\$380/\$190 =		+ 0						116/216	
		(3 mos)		\$870/\$435 =								117/217	
7. Enter any previous extension fee paid since above original due date and subtract													
8.								Extension Fee Attached		+ 0			
9. If Terminal Disclaimer attached, add Rule 20(d) official fee								+ \$110/\$55 =		+ 0		148/248	
10. If IDS attached requires Official Fee,		add		+ \$240 =						+ 0		126	
or if Rule 97(d) Petition		add		+ \$130 =								122	
11. After-Final Request Fee per rules 129(a) and 17(r)				+ \$760/380 =						+ 0		146/246	
12. No. of additional inventions for examination per Rule 129(b)				x \$760/380 ea =						+ 0		149/249	
13. Petition fee for										+			
14.								TOTAL FEE ENCLOSED =		\$0			

15. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

16. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

17. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown in the heading hereof, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Madison & Sutro LLP
Intellectual Property Group

By Atty: Carl G. Love

Reg. No. 18781

1100 New York Avenue, N.W.
Ninth Floor East Tower
Washington, D.C. 20005-3918
Tel: (202) 861-3000
Atty/Sec: CGL/lmr

Sig:

Fax: (202) 822-0944
Tel: (202) 861-3518

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments